In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.67 a new company low.

Within Major Pharmaceutical Preparations industry 307 other companies have achieved higher Quick Ratio than Nuvectis Pharma Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1036 to 1547.

Explain Quick Ratio?
How much Cash & cash equivalents NVCT�s has?
What are NVCT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NVCT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	32.15 %	25.68 %	49.49 %	82.11 %	84.25 %
Y / Y Cash & cash equivalent Change	-17.29 %	-15.85 %	70.69 %	106.43 %	47.9 %
Quick Ratio MRQ	1.67	2.25	2.38	3.08	2.66
NVCT's Total Ranking	# 1547	# 1036	# 995	# 757	# 435
Seq. Current Liabilities Change	18.93 %	-15.93 %	15.6 %	14.33 %	13.11 %
Seq. Cash & cash equivalent Change	-11.82 %	-20.56 %	-10.74 %	32.28 %	-10.28 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 308
Healthcare Sector	# 540
Overall Market	# 1547

Quick Ratio Statistics
High	Average	Low
6.14	3.78	1.67
(Sep 30 2022)		(Jun 30 2026)

Financial Statements
Nuvectis Pharma Inc 's Current Liabilities	$ 13 Millions	Visit NVCT's Balance sheet
Nuvectis Pharma Inc 's Cash & cash equivalent	$ 22 Millions	Visit NVCT's Balance sheet
Source of NVCT's Sales		Visit NVCT's Sales by Geography

Cumulative Nuvectis Pharma Inc 's Quick Ratio

NVCT's Quick Ratio for the trailling 12 Months

NVCT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	44.22 %	55.72 %	65.97 %	63.71 %	47.65 %
Y / Y Cash & cash equivalent TTM Growth	23.83 %	42.2 %	68.85 %	21.61 %	-3.66 %
Quick Ratio TTM	2.32	2.58	2.83	2.81	2.7
Total Ranking TTM	# 3789	# 3010	# 2855	# 2982	# 1762
Seq. Current Liabilities TTM Growth	7.02 %	5.22 %	11.19 %	15.18 %	15.56 %
Seq. Cash & cash equivalent TTM Growth	-3.89 %	-3.83 %	11.84 %	19.78 %	10.37 %

Quick ratio ranking by company, industry and sector >> Back to NVCT Financial Strength Comparisons >> Go to Compare NVCT Quick Ratio to its Competitors

News about Nuvectis Pharma inc Quick Ratio

Nuvectis Pharma Advancements in NSCLC Treatment Amidst Financial Challenges

In a significant stride towards improving the treatment landscape for non-small cell lung cancer (NSCLC), Nuvectis Pharma has announced the publication of a research study conducted at the Lerner Research Institute, part of the Cleveland Clinic at Case Western Reserve University. The study highlights the potential of the combination of NXP900 and epidermal growth factor receptor (EGFR) inhibitors to enhance the efficacy of existing EGFR inhibitors in preclinical models of EGFR-mutated NSCLC. This research offers a ray of hope to patients suffering from this challenging form of lung cancer, as the effectiveness of current therapies is often hampered by resistance mechanisms that develop over time.NXP900, an investigational therapeutic agent, has showcased promising results in the preclinical stage. The combination therapy utilizing NXP900 along with traditional EGFR inhibitors could potentially overcome existing therapeutic limitations, helping to combat the resistance seen in many NSCLC patients. This research adds to the growing body of evidence supporting the advancement of combination therapies in oncology, particularly for cancers driven by specific genetic mutations.

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $13.29 millions, cumulative Quick Ratio decreased to 2.32 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Nuvectis Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3010 to 3789.

Explain Quick Ratio?
How much Cash & cash equivalents NVCT�s has?
What are NVCT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 431
Healthcare Sector	# 878
Within the Market	# 3789

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.69	3.54	2.32
(Dec 31 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Viking Therapeutics Inc	4.57	$ 501.663 Millions	$ 109.656 Millions
Camp4 Therapeutics Corporation	4.51	$ 86.398 Millions	$ 19.142 Millions
Rein Therapeutics Inc	4.49	$ 43.627 Millions	$ 9.709 Millions
Quantum Cyber N v	4.46	$ 13.415 Millions	$ 3.005 Millions
Maia Biotechnology Inc	4.41	$ 27.596 Millions	$ 6.258 Millions
Azitra Inc	4.40	$ 6.728 Millions	$ 1.531 Millions
Cypherpunk Technologies Inc	4.39	$ 7.624 Millions	$ 1.737 Millions
Rigel Pharmaceuticals Inc	4.35	$ 225.347 Millions	$ 51.858 Millions
Biohaven Ltd	4.28	$ 267.866 Millions	$ 62.658 Millions
Incannex Healthcare Inc	4.25	$ 67.711 Millions	$ 15.940 Millions
Longeveron Inc	4.20	$ 18.104 Millions	$ 4.307 Millions
Vistagen Therapeutics Inc	4.15	$ 46.439 Millions	$ 11.192 Millions
Gyre Therapeutics Inc	4.12	$ 86.289 Millions	$ 20.957 Millions
Seaport Therapeutics Inc	4.11	$ 64.423 Millions	$ 15.674 Millions
Prelude Therapeutics Inc	3.99	$ 151.757 Millions	$ 38.042 Millions
Alx Oncology Holdings Inc	3.97	$ 22.753 Millions	$ 5.731 Millions
Actinium Pharmaceuticals Inc	3.94	$ 36.473 Millions	$ 9.260 Millions
Veru Inc	3.88	$ 23.880 Millions	$ 6.156 Millions
Gain Therapeutics inc	3.81	$ 13.084 Millions	$ 3.434 Millions
Bolt Biotherapeutics Inc	3.79	$ 29.823 Millions	$ 7.867 Millions
Acurx Pharmaceuticals inc	3.72	$ 10.656 Millions	$ 2.865 Millions
Maplight Therapeutics Inc	3.71	$ 71.633 Millions	$ 19.294 Millions
Aptevo Therapeutics Inc	3.47	$ 17.997 Millions	$ 5.188 Millions
Ataibeckley Inc	3.43	$ 168.807 Millions	$ 49.221 Millions
Dogwood Therapeutics inc	3.40	$ 9.628 Millions	$ 2.831 Millions
Tvardi Therapeutics Inc	3.39	$ 30.865 Millions	$ 9.113 Millions
Biomea Fusion Inc	3.32	$ 34.824 Millions	$ 10.483 Millions
Abeona Therapeutics Inc	3.32	$ 146.826 Millions	$ 44.233 Millions
Foghorn Therapeutics Inc	3.31	$ 167.582 Millions	$ 50.579 Millions
Cingulate Inc	3.29	$ 28.403 Millions	$ 8.631 Millions

Date modified: 2026-08-13T20:47:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.